New Jersey is currently home to 1678 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
Recruiting
The purpose of this study is to test any good and bad effects of the study drug called brentuximab vedotin at a lower dose than is FDA-approved.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/18/2024
Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey
Conditions: Mycosis Fungoides, Lymphomatoid Papulosis, Sezary Syndrome
Neuroblastoma Maintenance Therapy Trial
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
09/18/2024
Locations: Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Neuroblastoma
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
Recruiting
A Phase 1/2a First-in-Human Study of DB-1419 in Advanced/Metastatic Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/17/2024
Locations: Site USA04-0, Edison, New Jersey
Conditions: Solid Tumor, Adult
Brentuximab Vedotin and Nivolumab for the Treatment of Patients with Relapsed/refractory Classical Hodgkin Lymphoma
Recruiting
This phase II trial investigates how well brentuximab vedotin and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back after initial treatment (relapsed) or has not responded to initial treatment (refractory). Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Nivolumab is an antibody that enhances the immune sys... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/17/2024
Locations: Hackensack University Medical Center/John Theurer Cancer Center, Hackensack, New Jersey
Conditions: Relapsed Classic Hodgkin Lymphoma
RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT
Recruiting
The RSSearch® Registry is an international multi-year database designed to track SRS/SBRT (Stereotactic Radiosurgery/Stereotactic Body Radiation Therapy) utilization, treatment practices and outcomes to help determine, over time, the most effective use of these systems in management of patients with life threatening tumors and other diseases. (This study was formally called ReCKord and included the CyberKnife only; The ReCKord study continues as a CyberKnife subset of RSSearch.)
Gender:
ALL
Ages:
All
Trial Updated:
09/17/2024
Locations: AtlantiCare Regional Medical Center and AtlantiCare Cancer Care Institute, Egg Harbor Township, New Jersey
Conditions: Neoplasms, Arteriovenous Malformation of Central Nervous System, Trigeminal Neuralgia
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
Recruiting
NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors. The Phase 1 portion include patients with advanced solid tumors and is designed to determine the safety and the tolerability of doses of NUV-1511. In Phase 2, NUV-1511 will be given to determine the efficacy of patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/13/2024
Locations: Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer, Platinum-resistant Ovarian Cancer (PROC)
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Recruiting
This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The combinations to be evaluated are: * Arm 1: Selinexor + dexamethasone + pomalidomide (SPd); enrollment complete * Arm 2: Selinexor + dexamethasone + bortezomib (SVd); enrollment complete * Arm 3: Selinexor + dexamethas... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/12/2024
Locations: Hackensack University Medical Center - John Theurer Cancer Center, Hackensack, New Jersey
Conditions: Multiple Myeloma
Rectal Spacers Use in Prostate Cancer Radiation Therapy
Recruiting
This prospective, 2-arm clinical trial aims to evaluate the use of rectal spacers in patients with localized prostate cancer scheduled for Proton Beam Therapy (PBT). Up to 50 subjects will be enrolled in this study. Study visits will include screening, spacer placement, treatment planning, end-of-treatment assessment, and follow-up visits at 1, 3, and 6 months.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
09/10/2024
Locations: Procure Proton Therapy Center, Somerset, New Jersey
Conditions: Prostate Cancer
Breast Cancer Locator Guided vs. Wire Localized Partial Mastectomy for Breast Cancer
Recruiting
This prospective, multicenter, 1:1 randomized, controlled trial is designed to evaluate the safety and effectiveness of the Breast Cancer Locator (BCL) in subjects with non-palpable invasive breast cancer or ductal carcinoma in situ (DCIS). Subjects will be randomized to breast conserving surgery (BCS) utilizing either the BCL or wire localization (WL) to guide surgery.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/04/2024
Locations: Summit Health, Florham Park, New Jersey
Conditions: Breast Cancer Female
Phase III Presbyopia Correction Using the VIS Opti-K™ System
Recruiting
The goal of this clinical trial is to evaluate the safety and efficacy of using the VIS Opti-K System to enable monovision by providing temporary improvement in near vision through the treatment of the non-dominant eye of low myopic, emmetropic and low hyperopic presbyope subjects. The main questions it aims to answer are determining uncorrected near visual acuity at 40cm in the treated eye and subjective improvement as measured by the patient satisfaction questionnaire.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/30/2024
Locations: The Cornea & Laser Eye Institute, Teaneck, New Jersey
Conditions: Presbyopia
Continued Access Study to Evaluate Performance of the Organ Recovery Systems _LifePort® Liver Transporter System, a Machine Perfusion System, for Liver Transplant (PILOT™_CA)
Recruiting
To provide continued access for the LLT system to provide additional safety data in support of the PILOT pivotal efficacy and safety trial
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/29/2024
Locations: Rutgers New Jersey Medical School, Newark, New Jersey
Conditions: Liver Transplantation
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
Recruiting
The purpose of this study is to look at pulmonary exacerbations in people with cystic fibrosis (CF) that need to be treated with antibiotics given through a tube inserted into a vein (intravenous or IV). A pulmonary exacerbation is a worsening of respiratory symptoms in people with CF that needs medical intervention. Both doctors and CF patients are trying to understand the best way to treat pulmonary exacerbations. This study is trying to answer the following questions about treating a pulmonar... Read More
Gender:
ALL
Ages:
6 years and above
Trial Updated:
08/23/2024
Locations: Morristown Medical Center, Morristown, New Jersey
Conditions: Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation